| Document |
Document Title |
|
WO/2023/233346A1 |
The present invention relates to compounds having general formula ( I ) and to their uses for simultaneously modulating the bile acid receptors, FXR and GPBAR1, and the orphan receptor ROR gamma (RORγ) and thus to their use in the treat...
|
|
WO/2023/227723A1 |
The present invention relates to an improved process for the preparation of Aramchol and its pharmaceutically acceptable salts comprising the reaction of the corresponding 3. beta. -amine compound with a mixed anhydride of arachidic acid...
|
|
WO/2023/213540A1 |
The present invention relates to a process for the preparation of cholic acid derivatives, in particular of compounds of formula (V). The present invention also relates to compounds useful for the preparation of such derivatives.
|
|
WO/2022/232602A9 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. These compounds are conjugates of glucocorticoids with rho-kinase inhibitors. Also provided herein are methods of t...
|
|
WO/2023/208988A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt and/or solvates thereof. The invention further relates to the use of the compounds of the invention as anti-infective agents. In particular, ...
|
|
WO/2023/205447A2 |
The present invention relates to FXR agonist compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver, for example, severe alcohol-associated ...
|
|
WO/2023/205801A2 |
The invention describes novel steroidal compounds, compositions containing the same, and methods of using the same as SREBP inhibitors, as LXR agonists, or as dual modulators of SREBP and LXR, to treat SREBP and/or LXR mediated diseases.
|
|
WO/2023/185673A1 |
Provided in the present invention are CDK8 inhibitors, a preparation method therefor and the use thereof, belonging to the field of biological medicines. The CDK8 inhibitors of the present invention are compounds represented by formula (...
|
|
WO/2023/178299A1 |
This disclosure relates to ganaxolone derivatives, as well as methods of using the compounds (e.g., for treatment of a disease or disorder), methods of making the compounds, and pharmaceutical compositions and kits comprising the same.
|
|
WO/2023/173846A1 |
A steroid compound and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The structural formula of the steroid compound is as shown in formula I', wherein R is dimethylamino or methylamino. Th...
|
|
WO/2023/172909A1 |
The present embodiments are directed, in part, to methods of treating subjects suffering from estrogen receptor and progesterone receptor positive cancer by administering a combination of a selective estrogen receptor modulator (SERM) an...
|
|
WO/2023/168974A1 |
A cholic acid derivative, a preparation method therefor, and an application thereof as a TGR5 allosteric agonist. using CA as a lead compound, modification is performed at positions 7, 12, and 24 thereof by means of a series of reactions...
|
|
WO/2023/146842A9 |
Compositions of C25 stereodefined aminosterols and methods of making the same and using the same in therapeutic applications.
|
|
WO/2023/148764A1 |
The present invention is to design and develop novel synthetic cholic acid derivatives for treating autoimmune disorders/inflammatory conditions, process of synthesis of the compounds, compositions comprising the said compounds and use o...
|
|
WO/2023/143400A1 |
Provided are a steroid compound, a preparation method therefor and a use thereof. The steroid compound may have a structure as shown in formula VI. The compound has SREBP pathway inhibitory activity, and can be used for preventing and/or...
|
|
WO/2023/122752A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/105494A1 |
The present invention relates to cationic steroid compounds of formula (I) and methods of obtaining them. The present invention further relates to the incorporation of such compounds in a polymeric matrix composition or a coating composi...
|
|
WO/2023/103929A1 |
Provided are a fulvestrant derivative, and a preparation method therefor and the medical use thereof. Specifically, provided are a fulvestrant derivative represented by general formula (I), a preparation method therefor, a pharmaceutical...
|
|
WO/2023/086438A1 |
Prodrugs of neurosteroid analogs are disclosed. Pharmaceutical formulations containing the prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the prodrugs or their pharmaceutical formul...
|
|
WO/2023/083343A1 |
Among other things, the present disclosure provides technologies, e.g., compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is ...
|
|
WO/2023/083978A1 |
The present disclosure concerns the novel compound 3. alpha.- ethynyl-3. beta.-hydroxy-5. alpha.-androstan-17-methoxime, the medical use thereof and in particular use in the treatment of diseases and disorders associated with an a3 subty...
|
|
WO/2023/081166A1 |
Methods of making 5.beta-steroids by stereoselective hydrogenation of the corresponding 4(5)-unsaturated starting compounds, said method employing a solvent comprising at least 10% of pyridine or a substituted pyridine.
|
|
WO/2023/079362A1 |
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment o...
|
|
WO/2023/081658A2 |
Methods of making cholic acid derivatives, particularly TUDCA, preferably from non- animal sources, having exceptional purity and therapeutic utility.
|
|
WO/2023/076605A1 |
The present invention relates to lipid amine compounds of formula (A1) which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/076598A1 |
Provided are lipid amine compounds which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/048453A1 |
The present invention relates to nanoparticles comprising a drug dimer, and a use thereof. In addition, the nanoparticles may further comprise fucoidan. The nanoparticles comprising an obeticholic acid dimer compound can be used for trea...
|
|
WO/2023/040851A1 |
The present invention relates to the field of medicine, and specifically relates to a compound represented by formula I, a racemate, a stereoisomer, a tautomer, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, where...
|
|
WO/2023/028278A2 |
Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I) : and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are con...
|
|
WO/2023/003863A1 |
The present disclosure describes novel processes and intermediates for making onapristone.
|
|
WO/2022/238572A1 |
The invention relates to a synthesis of cholesterol; a ring opening step of the compound of formula (I) and subsequent activation and reduction step yielding cholesterol. The inventions relates also to intermediates achieved during said ...
|
|
WO/2022/232945A1 |
Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune ...
|
|
WO/2022/165512A9 |
Described herein are novel LIF/LIFR inhibitors that exhibit improved cytotoxicity and bioavailability. These LIF/LIFR inhibitors are particularly useful for the treatment of tumors associated with overexpression of LIF.
|
|
WO/2022/196858A1 |
The present invention relates to a novel amino acid derivative, a preparation method therefor, and a pharmaceutical composition for treating hepatitis B or D, comprising same. A compound represented by chemical formula 1, according to th...
|
|
WO/2022/171101A1 |
The present application relates to a steroid conjugate, and in particular, to a compound or a tautomer, a mesomer, a racemate, an enantiomer, and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt...
|
|
WO/2022/142385A1 |
The present invention provides a method for refining dienogest. The method is a recrystallization method. The present invention belongs to the technical field of medicine synthesis. The refining of dienogest comprises the following steps...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/091136A1 |
The present disclosure provides a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The present disclosure also reveals ...
|
|
WO/2022/059948A1 |
The present invention relates to a method for mass-producing sodium taurodeoxycholate, wherein isopropyl alcohol is used in order to produce the sodium taurodeoxycholate commercially, and separation and purification are carried out using...
|
|
WO/2022/039983A2 |
Methods of making cholic acid derivatives, particularly ursodeoxycholic acid, tauroursodeoxycholic acid, 7-ketolithocholic acid, obeticholic acid, their carboxyl ate salts and carboxyl ate esters, and starting materials and intermediates...
|
|
WO/2022/022623A1 |
The present invention belongs to the technical field of medicine, and particularly relates to an arenobufagin derivative, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. The arenobufagin derivati...
|
|
WO/2022/006145A1 |
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/236953A1 |
Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R...
|
|
WO/2021/213984A1 |
The present invention relates to a new synthesis of 7- dehydrocholesterol or itsOH-protected forms of the formula I by the reaction of a compound of formula (ll)in the presence of a solvent of formula (III), comprising the step (a) where...
|
|
WO/2021/214685A1 |
The present invention refers to a method for the preparation of a compound of formula (I).
|
|
WO/2021/213988A1 |
The present invention relates to the purification of 7-dehydrocholesterol or 25-hydroxy-7-dehydrocholesterol or their OH-protected forms, respectively. It has been found that the process using organic solvent nanofiltration allows an eff...
|
|
WO/2021/194298A1 |
The present invention relates to nanoparticles comprising drug dimers, and a use thereof. The nanoparticles comprising drug dimers, of the present invention, can increase drug content and improve the drug dispersibility. In addition, the...
|
|
WO/2021/184789A1 |
Disclosed in the present invention are an epristeride impurity, and a preparation method therefor and the use thereof, which fall within the field of medicinal chemistry. The chemical name of the epristeride impurity is 17β-(N-tert-buty...
|
